CATEGORIES
Kategoriler
Exempt Healthcare Services From GST
Exempt Healthcare Services From GST
NCDs Alarm Demands Bold Steps
India is first country to develop targets, indicators to reduce global premature deaths from NCDs by 25 per cent by 2025.
Acquisition Of Janssen Products Has Strengthened Our Product Range
Piramal Critical Care, a leader in the field on anaesthesia, both inhaled and intravenous, is expanding business globally.
Effort Towards Training & Skill Devp Of Life Sciences Talent Pool
India has about 500 recognised universities and 26,000 colleges, some of them holding worldwide ranking (according to agencies conducting ranking surveys).
Meet Addresses Need Of Innovation And Research Towards Solving Problems Of Society
The theme ‘Impacting the Biotech Innovation Ecosystem’ aptly reflected the Fifth Foundation Day of Biotechnology Industry Research Assistance Council (BIRAC) that was celebrated recently.
from super computing to health informatics
prof. rajat moona director general, c-dac spread across 11 centres in india, the centre for development of advanced computing, better known as c-dac, is working silently to usher in a healthcare revolution through ict. here’s an exclusive interview with c-dac’s director general, prof. rajat moona
“Indian Customer Will Continue To See New Product Development”
SpectrumLabs.com is a global player in membrane separation technologies for the pharmaceutical, bioprocess, diagnostic and research industries. Spectrum focuses on two core technologies, Single-Use Hollow Fiber Tangential Flow Filtration and Tubular Membrane Dialysis.
India Needs Proper Biosupplier Ecosystem
With economic growth and addition of biotechnology to its portfolio, India is rapidly becoming a global player in the life sciences and healthcare space. Educating and achieving scientific excellence demands a really high level of R&D. Now that the government is investing more resources in research and medical facilities and infrastructure, from educational institutes to hospitals, use of lab equipment, reagents or medical devices are growing rapidly. This will drive the growth of biosupplier market in the country.
“Data Sharing, Post Study Access To Trial Medication Are Emerging Frontiers”
“Data Sharing and Post study access to trial medication for study subjects are the two emerging frontiers in clinical research space,” said Dr Saral Thangam, CEO & Managing Director, Norwich Clinical Services.
Biotechnology - Where Is It Heading?
On one hand, the biotechnology industry is starved of skilled talent pool. On the other hand, there are several universities and colleges, producing number of unemployable graduates. While some of them are struggling due to lack of students. So serious thinking needs to be done urgently to overcome this problem.
Pharma Exporters To US Under Pressure
Recent USFDA hike of fee for processing ANDA will certainly going to put immense pressure on the Indian pharma industry, resulting eviction of many small players from this pharma export business.
“We Have Streamlined The Whole Process Of Reviewing And Approval”
Indian Council of Medical Research (ICMR) signed an agreement recently with other global agencies to develop and implement policies within the next 12 months that require all trials they fund, co-fund, sponsor or support to be registered in a publicly available registry.
“Private Sector, Government Need To Work Together To Make Healthcare Accessible In Rural India”
For the first time National Heath Policy is talking about the preventive healthcare and wellness. From the statement point of view, it is really a commendable thing but now it has to be translated on to the ground. Harish Pillai COO, Indus Health Plus in an interaction with BioSpectrum India talks about why preventive healthcare is the need of the hour and how it can be successful.
Make In India' - A Major Boon To Medical Technology Industry
Having a solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 165 countries for the last 20 years. Today, Trivitron Healthcare, through successful inorganic synergies with local and global firms, has a revenue turnover of Rs 750 crore. BioSpectrum India spoke to Dr GSK Velu, Chairman & Managing Director, Trivitron Healthcare Group of Companies to about the status of medical technology market in India and competition coming from Chinese medical devices.Excerpts of the interview
Association Of Indian Medical Device Industry (AIMED) Recommendations
Association Of Indian Medical Device Industry (AIMED) Recommendations
Medical Devices Rules, 2017 Opens Up Enormous Opportunities
The new Medical Devices Rules, 2017 seek to remove regulatory bottlenecks to make in India, facilitate ease of doing business while ensuring availability of better medical devices for patient care and safety. The rules will also regulate a much larger set of medical devices under a framework customized for medical devices. The stakeholders are hoping that the system will be industry friendly and will indeed create an ecosystem that will enable to boost medical technology innovation and manufacturing in the country.
Natco Pharma Plans API Expansion With More Investment
Hyderabad-based Natco Pharma is planning to expand its Active Pharmaceutical Ingredient (API) and intermediates manufacturing facility in Tamil Nadu. The company is looking at investing in its existing facility, in Thiruvallur District.
IP In Start-Up Ecosystem
In this age of innovation and technology, Intellectual Property (IP) is an essential element for an organization to sustain and flourish over long periods of time. This is particularly applicable for organizations which rely heavily on R&D to develop technology based solutions for existing problems, and the biotech startup community is no different.
India To Bounce Back As Clinical Research Hub
India was considered as an all-time favoured destination for clinical trials. Most of the outsourced studies are phase III studies where India has a diverse pool of patients. After 2010 there was major setback in the CRO industry in India. Drug Controller General of India (DCGI) approvals were delayed and multinational sponsors stepped back outsourcing studies to India. But slowly post 2016 DCGI has been generous enough in proving approvals and online application system has brought a lot of difference. Indian Clinical Trial market and clinical trial services is expected to grow significantly along with trends.
PE Giants Eyeing Stake At Mankind Worth Crores
Big private equity firms and sovereign wealth funds are exploring a purchase deal share worth at least Rs 5,000-crore ($750-million) in India’s fifth largest drug maker Mankind Pharma.
Promoting Affordable Healthcare
WITH MORE THAN 25 YEARS OF EXPERIENCE IN HEALTHCARE, TERRI BRESENHAM HAS MADE SEVERAL CONTRIBUTIONS TOWARDS ADDRESSING GLOBAL HEALTH ISSUES
Assisting Breast Cancer Diagnosis
AFTER LEADING THE CANCER DRUG DISCOVERY AND MULTI-DISCIPLINARY RESEARCH ON ‘POINT-OF-CARE’ DIAGNOSTICS AT RENOWNED COMPANIES, DR MANJIRI M. BAKRE IS NOW DEVELOPING COST EFFECTIVE AND RELIABLE TESTS FOR PERSONALIZED CANCER TREATMENT.
Transforming Hair & Skin Care
A DOCTORATE IN TRICHOLOGY HELPED DR BANI ANAND TO TAKE HAIR & SKIN CARE TREATMENT FROM NON-SURGICAL COMPETENCIES TO SURGICAL TREATMENT OPTIONS.
Enhancing Clinical Drug Developments
WITH HER 20 YEARS OF EXPERIENCE, BINDHYA CARIAPPA IS WORKING ON PUTTING INDIA ON THE GLOBAL CLINICAL TRIAL MAP.
Biotech Parks Relevance & Untapped Potential
With effective regulatory framework, government and private support, biotechnology parks can provide an ideal platform for companies, universities and R&D institutes to promote bioactivities.
Demand For Specialised Infrastructure, Incubators Continues To Be Moderate To Strong
Utkarsh Palnitkar says only a few biotech parks support industry with ready-to-use lab facilities for R&D, incubation support for start-ups and dedicated land for scaling up activities are operational in India.
Agilent In Agreement With Agendia For Cancer Diagnostics
Agilent Technologies Inc. and Agendia, Inc. have jointly announced an agreement to expand their relationship to include the development of an RNA Seq kit version of Agendia’s currently marketed Mamma Print and Blueprint tests.
Nanoparticles For Treating Eye Infections
Scientists at the Hyderabad-based CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) have developed a novel way to treat fungal keratitis.
Global Pharma Continues To See Potential In Investing In R&D In India
Innovative biopharmaceutical companies around the world continue to strive to accelerate the pace of innovation and deliver effective medicines to patients quickly and efficiently. By investing more time, energy, and resources in collaboration across the R&D ecosystem and leveraging more sophisticated research and manufacturing tools, these companies in India continue to invest in R&D and advance the science forward.
Competition Is Getting Fierce Among The 'Health Startups' In India
Medical care is just a click away but this has also blown a trumpet of online combat between these startups. Currently, it may look like a wide field to play in but in the coming years, there will be more players joining these online battle and then it will become a cut throat competition